Peter Rahmer - Jan 28, 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jan 28, 2025
Transactions value $
-$204,753
Form type
4
Date filed
1/30/2025, 09:16 PM
Previous filing
Jan 14, 2025
Next filing
Mar 31, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale -$7.75K -1.67K -0.54% $4.63 307K Jan 28, 2025 Direct F1, F2
transaction RLAY Common Stock Award $0 +139K +45.31% $0.00 446K Jan 28, 2025 Direct F3, F4
transaction RLAY Common Stock Sale -$121K -26.5K -5.95% $4.55 420K Jan 29, 2025 Direct F5, F6
transaction RLAY Common Stock Sale -$76.2K -17.3K -4.11% $4.42 402K Jan 30, 2025 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2 Includes 284,033 shares underlying RSUs.
F3 Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
F4 Includes 423,174 shares underlying RSUs.
F5 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 100,000 shares of RSUs on January 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F6 Includes 323,174 shares underlying RSUs.
F7 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F8 Includes 253,604 shares underlying RSUs.

Remarks:

Chief Corporate Development Officer